Essais liés10clinical trials
VilleWestmeadlocalisation
PaysAustralialocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT05716100

Ouvrir le site du centre

Essais cliniques associés

10
MoléculeIndication / populationPhaseNCTTitreStatut
Pumitamig Cancer Phase 3 NCT07173751 ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer RECRUITING
Physiology-guided NCL PCI Maladie coronarienne Non applicable NCT05701358 COMPLETE-2 — Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease ACTIVE_NOT_RECRUITING
FARAPULSE™ Pulsed Field Ablation System Maladie coronarienne Non applicable NCT06735534 ReMATCH — Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System ACTIVE_NOT_RECRUITING
Rituximab SEP Phase 3 NCT00004179 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma COMPLETED
Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation Maladie coronarienne Non applicable NCT06272981 PulseSmart — A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS COMPLETED
PF-08634404 Cancer Phase 2 NCT07476287 Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer RECRUITING
Arm A: Gedatolisib + Palbociclib + Fulvestrant Cancer Phase 3 NCT06757634 Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) RECRUITING
XEN1101 Épilepsie Phase 3 NCT05716100 A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) RECRUITING
Acoramidis Alzheimer Phase 3 NCT06563895 Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant RECRUITING
Prasinezumab Parkinson Phase 3 NCT07174310 PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease RECRUITING